PF-03187207
- Generic Name
- PF-03187207
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.
- Indication
Investigated for use/treatment in glaucoma and ocular hypertension.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 117
- Registration Number
- NCT00595101
- Locations
- 🇯🇵
Pfizer Investigational Site, Shizuoka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath